MedTrace Logo

Study of Anginera in Adults With a Left Ventricular Assist Device (LVAD) as Bridge to Transplant

NCT00364598 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2009-03-30

No results posted yet for this study

Summary

The purpose of this study is to obtain human heart tissue after treatment with Anginera to determine its effect on a variety of things that might indicate improvement in heart function. Patients who will have a left ventricular assist device (LVAD) implanted while they wait for a donated heart will be treated with Anginera. At the time of heart transplant, their diseased heart which is removed will be analyzed by microscopic examination to see what effect Anginera had.

Conditions

Interventions

DRUG

Anginera, a human tissue replacement therapy

Sponsors & Collaborators

  • Theregen, Inc.

    lead INDUSTRY

Principal Investigators

  • Kenneth B Margulies, M.D. · University of Pennsylvania

  • Y. Joseph Woo, M.D. · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-11-30
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00364598 on ClinicalTrials.gov